Training in Cancer Therapeutics Research

癌症治疗研究培训

• 批准号: 9331498
• 负责人: EDWARD CHU
• 金额: $ 28.94万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-25 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9331498
• 关键词: Malignant Neoplasms; Therapeutic Human Experimentation; Training

 DESCRIPTION (provided by applicant): Over the past 25-30 years, tremendous advances have been made in our fundamental understanding of the molecular genetics and biology that underlie the development of human cancer. This enhanced understanding of the critical hallmarks of cancer has led to an accelerated development of novel agents and treatment regimens to treat individual cancers, and an increasing number of new drugs are now being approved by the US Food and Drug Administration each year. However, despite these significant advances, there remain significant challenges to the ultimate clinical efficacy of thes new therapies whether they be cytotoxic chemotherapy, targeted therapy, and/or immunotherapy. In general, once advanced disease is diagnosed, the patient is incurable. As a result, there remains an urgent and critical need to train individuals with specific expertise in cancer therapeutics. It is especially important to train individuals with a solid understanding of basic science concepts who can then more effectively and successfully translate basic laboratory findings to the clinical setting as well as incorporate correlative science in clinical trials, which can subsequently inform the basic science. Unfortunately, there remains an insufficient level of interaction between basic scientists and translational/clinical investigators in large part because the two worlds are so different in their scope and priority. As such, we believe that the training of physician-scientists in both pre-clinical and clinical/translational science will greatly advance the field of cancer therapeutics with the eventual goal of developing novel agents and treatment regimens that can make a real difference in the lives of cancer patients. The successful treatment of human cancer requires an integrated multi- and inter-disciplinary approach. The University of Pittsburgh Cancer Institute (UPCI) and the Division of Hematology-Oncology are deeply committed to developing novel cancer therapeutics that span the entire range of classic cytotoxic chemotherapy agents, targeted therapies, immunologic agents, and biologic agents. This Training Program has brought together an outstanding group of investigators from the Division of Hematology-Oncology and from six other departments of the University of Pittsburgh School of Medicine, and the scientific expertise of the training faculy includes the entire continuum of pre-clinical, translational, and clinical cancer therapeutics research. This group of scientists understands the significance of training physician-scientists and proposes to achieve this goal by accomplishing the following aims: (1) Recruit highly promising medical oncology fellows, who are committed to a career in academic medical oncology relevant to the field of cancer therapeutics (2) Provide specific graduate-level course work to enhance their knowledge in molecular and cell biology, immunology, biochemistry, pharmacology, genetics, and clinical/translational medicine (3) Provide an in-depth exposure to basic research skills by working with well-established mentors who are focused on cancer therapeutics. This proposal is for a Training Program for medical oncology fellows that encompasses the entire range of cancer therapeutics research and includes basic, translational, and clinical science. Three medical oncology fellows will be supported for each year of the Program. This Training Program will focus on 5 defined research areas: (1) Cytotoxic Chemotherapy; (2) Targeted Molecular Therapy; (3) Immunotherapy; (4) Investigating Mechanisms of Chemosensitivity and Resistance; and (5) Clinical Investigations. Each of these research areas is well-represented by the members of our training faculty, and a representative of each research area is on the Executive Committee. The training experience will consist of formal course work, seminars, journal clubs, basic laboratory research, and clinical/translational research. Basic laboratory and translational research will form the bulk of the training experience. Each of the trainees will participate in graduate-level courses on the principles and techniques of cancer drug development, cancer biology, signaling, immunology, biochemistry, cell biology, genetics, and clinical trials, as well as courses on the responsible conduct of research each year, which will provide them with the necessary foundation to develop an academic career focused on cancer therapeutics. The trainees will enter a mentor's laboratory for two years, with an optional third year of training if approved by the Executive Committee. Assessment and evaluation will take place every 4 months and this evaluation will be presented to the Executive Committee. Following the Committee meeting, the trainee meets with the Program Director, at which time, the trainee will be asked to evaluate his/her experience in the mentor's laboratory. A two-page written summary by each trainee evaluating their overall training experience is required at the conclusion of the research fellowship. We anticipate that this feedback from faculty and trainees, respectively, will enhance the overall academic productivity of the program.

 描述（由申请人提供）：在过去的 25-30 年中，我们对人类癌症发展的分子遗传学和生物学的基本理解取得了巨大进步，这增强了对癌症关键特征的理解。治疗个体癌症的新药和治疗方案的加速开发，美国食品和药物管理局每年批准越来越多的新药。然而，尽管取得了这些重大进展，但最终的临床仍然存在重大挑战。功效无论是细胞毒性化疗、靶向治疗还是免疫治疗，一旦诊断出晚期疾病，患者就无法治愈，因此仍然迫切需要培训具有癌症专业知识的个人。培训对基础科学概念有深入理解的个人尤为重要，他们可以更有效、更成功地将基本实验室发现转化为临床环境，并将相关科学纳入临床试验，从而为基础科学提供信息。不幸的是，双方之间的互动程度仍然不足。基础科学家和转化/临床研究人员在很大程度上是因为这两个世界的范围和优先事项如此不同，因此我们相信临床前和临床/转化科学方面的医师科学家培训将极大地推动该领域的发展。匹兹堡大学癌症研究所的癌症治疗研究的最终目标是开发能够真正改变癌症患者生活的新型药物和治疗方案。 （UPCI）和血液肿瘤科致力于开发涵盖所有经典细胞毒性化疗药物、靶向治疗、免疫制剂和生物制剂的新型癌症疗法。该培训计划汇集了来自血液肿瘤科的优秀研究人员团队。 -来自匹兹堡大学医学院的肿瘤学和其他六个系，培训教师的科学专业知识包括临床前、转化和临床癌症治疗研究的整个连续体。培训医师科学家的重要性，并建议通过实现以下目标来实现这一目标：（1）招募非常有前途的肿瘤内科研究员，他们致力于与癌症治疗领域相关的学术肿瘤学职业生涯（2）提供特定的研究生水平课程，以增强他们在分子和细胞生物学、免疫学、生物化学、药理学、遗传学和临床/转化医学方面的知识 (3) 通过与成熟的专家合作，深入了解基础研究技能该提案针对肿瘤内科研究员的培训计划，涵盖整个癌症治疗研究范围，包括基础、转化和临床科学。该计划每年将支持三名肿瘤内科研究员。 5个明确的研究领域：（1）细胞毒性化疗；（3）靶向分子治疗；（4）研究机制化学敏感性和耐药性；以及 (5) 临床研究 每个研究领域都有我们的培训教师代表，并且每个研究领域的代表都在执行委员会中。 、研讨会、期刊俱乐部、基础实验室研究以及临床/转化研究将构成培训经验的大部分。每位学员将参加有关癌症药物开发原理和技术的研究生课程。 , 癌症生物学,信号学、免疫学、生物化学、细胞生物学、遗传学和临床试验，以及每年有关负责任的研究行为的课程，这将为他们进入专注于癌症治疗的学术职业提供必要的基础。导师实验室为期两年，如果执行委员会批准，则可选择进行第三年的培训。评估和评估将每 4 个月进行一次，评估结果将在委员会会议后提交给执行委员会。项目总监，当时，受训者将被要求评估他/她在导师实验室的经历。在研究奖学金结束时，每个受训者都需要一份两页的书面总结来评估他们的整体培训经历。分别将提高该计划的整体学术生产力。